Clinical Controversies in the Management of Metastatic Colorectal Cancer

Select Publications

HOCHSTER

Abdalla EK et al. **Improving resectability of hepatic colorectal metastases: Expert consensus statement.** *Ann Surg Oncol* 2006;13(10):1271-80.

Adam R et al. **Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival.** *Ann Surg* 2004;240(4):644-57.

Adson MA et al. **Resection of hepatic metastases from colorectal cancer.** *Arch Surg* 1984;119(6):647-51.

Charnsangavej C et al. **Selection of patients for resection of hepatic colorectal metastases: Expert consensus statement.** *Ann Surg Oncol* 2006;13(10):1261-8.

Doci R et al. **One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinants.** *Br J Surg* 1991;78(7):797-801.

Donadon M et al. **New paradigm in the management of liver-only metastases from colorectal cancer.** *Gastrointest Cancer Res* 2007;1(1):20-7.

Fernandez FG et al. **Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).** *Ann Surg* 2004;240(3):438-47.

Folprecht G et al. **Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial.** *Lancet Oncol* 2010;11(1):38-47.

Folprecht G et al. **Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates.** *Ann Oncol* 2005;16(8):1311-9.

Gayowski TJ et al. **Experience in hepatic resection for metastatic colorectal cancer: Analysis of clinical and pathologic risk factors.** *Surgery* 1994;116(4):703-10.

Hughes KS et al. **Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors.** *Dis Colon Rectum* 1988;31(1):1-4.

McLoughlin JM et al. **Resection of colorectal liver metastases: Current perspectives.** *Cancer Control* 2006;13(1):32-41.

Nordlinger B et al. **Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial.** *Lancet* 2008;371(9617):1007-16.

Pawlik TM et al. **Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.** *Ann Surg* 2005;241(5):715-24.

Rees M et al. **Late results justify resection for multiple hepatic metastases from colorectal cancer.** *Br J Surg* 1997;84(8):1136-40.

Rosen CB et al. **Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma.** *Ann Surg* 1992;216(4):493-504.

Scheele J et al. **Indicators of prognosis after hepatic resection for colorectal secondaries.** *Surgery* 1991;110(1):13-29.

Scheele J et al. **Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history.** *Br J Surg* 1990;77(11):1241-6.

Vauthey JN et al. **Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.** *J Clin Oncol* 2006;24(13):2065-72.

ZALCBERG

Cassidy J et al. **Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies.** *J Cancer Res Clin Oncol* 2010;136(5):737-43.

Ellis LM, Hicklin DJ. **VEGF-targeted therapy: Mechanisms of anti-tumour activity.** *Nat Rev Cancer* 2008;8(8):579-91.

National Comprehensive Cancer Network (NCCN®). **NCCN clinical practice guidelines in oncology. Colon cancer — Version 1.2012.** Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

Van Cutsem E et al. **Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment.** *Ann Oncol* 2010;21(Suppl 5):v93-7.

VAN CUTSEM

Cunningham D et al. **Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.** *N Engl J Med* 2004;351(4):337-45.

Cunningham D et al. **Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.** *Lancet* 1998;352(9138):1413-8.

De Roock W et al. **Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis.** *Lancet Oncol* 2010;11(8):753-62.

Grothey A et al. **Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.** Gastrointestinal Cancers Symposium 2012;**Abstract LBA385**.

Grothey A et al. **Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE).** *J Clin Oncol* 2008;26(33):5326-34.

Hurwitz H et al. **Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.** *N Engl J Med* 2004;350(23):2335-42.

Rothenberg ML et al. **Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial.** *J Clin Oncol* 2003;21(11):2059-69.

Sobrero AF et al. **Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).** Gastrointestinal Cancers Symposium 2012;**Abstract 387**.

Tabernero J et al. **Results from VELOUR, a phase 3 study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer.** European Multidisciplinary Congress 2011;**Abstract 6LBA**.

Tabernero J et al. **Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.** *J Clin Oncol* 2007;25(33):5225-32.

Van Cutsem E et al. **Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): Results of a multinational phase III trial (EFC10262-VELOUR).** World Congress on Gastrointestinal Cancer 2011;**Abstract O-0024**.

Van Cutsem E et al. **Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.** *N Engl J Med* 2009;360(14):1408-17.

Van Cutsem E et al. **Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials.** *Br J Cancer* 2004;90(6):1190-7.

ARNOLD

Díaz-Rubio E et al. **First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study.** *Oncologist* 2012;17(1):15-25.

Folprecht G et al. **Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials.** *J Clin Oncol* 2008;26(9):1443-51.

Griebsch I et al. **The effect of tumor response on quality of life (QoL) in patients with KRAS wild-type metastatic colorectal cancer (mCRC): Analysis from the CRYSTAL study.** *Proc ASCO* 2011;**Abstract 3626**.

Grothey A et al. **Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.** Gastrointestinal Cancers Symposium 2012;**Abstract LBA385**.

Sargent DJ et al. **Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.** *J Clin Oncol* 2009;27(12):1948-55.

Seymour MT et al. **Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): An open-label, randomised factorial trial.** *Lancet* 2011;377(9779):1749-59.

Siena S et al. **Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial.** Gastrointestinal Cancers Symposium 2012;**Abstract 283**.

Tabernero J et al. **Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]).** *Proc ASCO* 2010;**Abstract 3501**.

VENOOK

Cook AD et al. **Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: An analysis of surveillance, epidemiology, and end results data, 1988 to 2000.** *Ann Surg Oncol* 2005;12(8):637-45.

McCahill LE et al. **A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10.** *Proc ASCO* 2010;**Abstract 3527**.